claim: therapeutically administered ribonucleoside analogue mk-4482/eidd-2801 blocks sars-cov-2 transmission in ferrets
evidence_1: we previously reported the development of an orally efficacious ribonucleoside analogue inhibitor of influenza viruses, mk-4482/eidd-2801 (refs.", "the samples from the source ferrets treated with mk-4482/eidd-2801 and their contacts were pcr-negative for viral rna.", "2: therapeutic mk-4482/eidd-2801 is orally efficacious against sars- cov-2 in ferrets.")